OBJECTIVE: To evaluate radiation techniques and their toxicity in the treatment of Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL) with mediastinal disease over a 10-year period. METHODS: Between 2003 and 2015, 173 patients with Stage I-III nodal lymphoma were treated in our institution: some of these patients were irradiated for HL or NHL with mediastinal disease. Some of the patients were treated by three-dimensional conformal radiotherapy (3DCRT), others by intensity-modulated radiotherapy (IMRT). RESULTS: We studied 26 males and 43 females with a median age of 26 years. The median follow-up was 43 months. 49 patients were treated by 3DCRT and 20 patients by IMRT. The median dose received by patients treated for NHL was 40 Gy (range: 36-44 Gy), and the median dose received by patients with HL was 30 Gy (range: 30-36 Gy). Between 2003 and 2006, 16 patients were treated by 3DCRT vs 0 patients by IMRT. Between 2007 and 2009, 16 patients received 3DCRT and one patient received IMRT. Between 2010 and 2015, 19 patients received IMRT, and no patients received 3DCRT. 11 of the 20 (55%) patients treated by IMRT and 35 of the 49 (71.4%) patients treated by 3DCRT experienced acute toxicity. Among the patients treated by 3DCRT, one patient experienced Grade 1 radiation pneumonitis and two patients experienced Grade 1 acute mucositis. No late toxicity was observed in patients treated by IMRT. CONCLUSION: Improvement of radiation techniques for HL and NHL appears to have improved acute and late clinical safety. Longer follow-up is necessary to evaluate very late toxicity. ADVANCES IN KNOWLEDGE: Improvement of radiation techniques for HL and NHL appears to improve the tolerance.
OBJECTIVE: To evaluate radiation techniques and their toxicity in the treatment of Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL) with mediastinal disease over a 10-year period. METHODS: Between 2003 and 2015, 173 patients with Stage I-III nodal lymphoma were treated in our institution: some of these patients were irradiated for HL or NHL with mediastinal disease. Some of the patients were treated by three-dimensional conformal radiotherapy (3DCRT), others by intensity-modulated radiotherapy (IMRT). RESULTS: We studied 26 males and 43 females with a median age of 26 years. The median follow-up was 43 months. 49 patients were treated by 3DCRT and 20 patients by IMRT. The median dose received by patients treated for NHL was 40 Gy (range: 36-44 Gy), and the median dose received by patients with HL was 30 Gy (range: 30-36 Gy). Between 2003 and 2006, 16 patients were treated by 3DCRT vs 0 patients by IMRT. Between 2007 and 2009, 16 patients received 3DCRT and one patient received IMRT. Between 2010 and 2015, 19 patients received IMRT, and no patients received 3DCRT. 11 of the 20 (55%) patients treated by IMRT and 35 of the 49 (71.4%) patients treated by 3DCRT experienced acute toxicity. Among the patients treated by 3DCRT, one patient experienced Grade 1 radiation pneumonitis and two patients experienced Grade 1 acute mucositis. No late toxicity was observed in patients treated by IMRT. CONCLUSION: Improvement of radiation techniques for HL and NHL appears to have improved acute and late clinical safety. Longer follow-up is necessary to evaluate very late toxicity. ADVANCES IN KNOWLEDGE: Improvement of radiation techniques for HL and NHL appears to improve the tolerance.
Authors: Tim Illidge; Lena Specht; Joachim Yahalom; Berthe Aleman; Anne Kiil Berthelsen; Louis Constine; Bouthaina Dabaja; Kavita Dharmarajan; Andrea Ng; Umberto Ricardi; Andrew Wirth Journal: Int J Radiat Oncol Biol Phys Date: 2014-05-01 Impact factor: 7.038
Authors: A Paumier; W Khodari; A Beaudre; M Ghalibafian; P Blanchard; H Al Hamokles; M Bhari; N Lessard; T Girinsky Journal: Cancer Radiother Date: 2011-11-23 Impact factor: 1.018
Authors: Lena Specht; Joachim Yahalom; Tim Illidge; Anne Kiil Berthelsen; Louis S Constine; Hans Theodor Eich; Theodore Girinsky; Richard T Hoppe; Peter Mauch; N George Mikhaeel; Andrea Ng Journal: Int J Radiat Oncol Biol Phys Date: 2013-06-18 Impact factor: 7.038
Authors: Andrea K Ng; Judy E Garber; Lisa R Diller; Robyn L Birdwell; Yang Feng; Donna S Neuberg; Barbara Silver; David C Fisher; Karen J Marcus; Peter M Mauch Journal: J Clin Oncol Date: 2013-04-22 Impact factor: 44.544
Authors: Niklaus G Schaefer; Thomas F Hany; Christian Taverna; Burkhardt Seifert; Katrin D M Stumpe; Gustav K von Schulthess; Gerhard W Goerres Journal: Radiology Date: 2004-07-23 Impact factor: 11.105
Authors: J Yahalom; J A Petrek; P W Biddinger; S Kessler; D D Dershaw; B McCormick; M P Osborne; D A Kinne; P P Rosen Journal: J Clin Oncol Date: 1992-11 Impact factor: 44.544
Authors: S Horn; N Fournier-Bidoz; V Pernin; D Peurien; M Vaillant; R Dendale; A Fourquet; Y M Kirova Journal: Cancer Radiother Date: 2016-03-15 Impact factor: 1.018
Authors: Andrea Riccardo Filippi; Sofia Meregalli; Anna DI Russo; Mario Levis; Patrizia Ciammella; Michela Buglione; Andrea Emanuele Guerini; Giuseppina De Marco; Vitaliana De Sanctis; Stefano Vagge; Umberto Ricardi; Gabriele Simontacchi Journal: Radiat Oncol Date: 2020-03-12 Impact factor: 3.481